Samsung Biologics (207940) stock
KOSPI · Pharmaceuticals
As of Nov 16, 12:45 PM KST
Events and reference metrics · 1
- Market cap
- KRW 65 trillion
- As of Nov 16, 2026
- P/E
- 32.75x
- Trailing twelve months
- P/B
- 7.77x
- Latest reported equity
- P/S
- 14.29x
- Trailing twelve months
- ROE
- 23.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 65 trillion
- As of Nov 16, 2026
- P/E
- 32.75x
- Trailing twelve months
- P/B
- 7.77x
- Latest reported equity
- P/S
- 14.29x
- Trailing twelve months
- ROE
- 23.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
32.75x
P/B
7.77x
P/S
14.29x
Earnings and dividend metrics▾
Earnings
EPS
KRW 42,866
Earnings per share
BPS
KRW 180,638
Book value per share
ROE
23.7%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 42,866 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 180,638 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 23.7%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 1.3 trillion | KRW 586.4 billion | KRW 430.7 billion | — |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 1.3 trillion | KRW 580.8 billion | KRW 469.2 billion | — |
| Q4 2025Consolidated · Filed May 15, 2026 | KRW 308.6 billion | KRW 378.1 billion | KRW 510 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 1.7 trillion | KRW 728.8 billion | KRW 574.5 billion | +39.9% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 1.3 trillion | KRW 475.6 billion | KRW 324.4 billion | +11.5% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 1.3 trillion | KRW 486.7 billion | KRW 375.6 billion | +37.1% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed May 15, 2026 | KRW 4.6 trillion | KRW 2.1 trillion | KRW 1.8 trillion | — |
| FY2024Consolidated · Filed Aug 14, 2025 | KRW 4.5 trillion | KRW 1.3 trillion | KRW 1.1 trillion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 24.96%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 21.43 billion
- Previous 20-day average 17.33%
- Net short position
- 381,095 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 1,039,239 shares
- As of Nov 13, 2026 · 2.25% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 24.96% | KRW 21.43 billion |
| Nov 12, 2026 | 50.98% | KRW 84.07 billion |
| Nov 11, 2026 | 22.29% | KRW 31.23 billion |
| Nov 10, 2026 | 18.01% | KRW 21.32 billion |
| Nov 9, 2026 | 32.32% | KRW 38.79 billion |
| Nov 6, 2026 | 11.88% | KRW 22.97 billion |
| Nov 5, 2026 | 16.66% | KRW 28.18 billion |
| Nov 4, 2026 | 14.72% | KRW 20.43 billion |
| Nov 3, 2026 | 16.79% | KRW 16.65 billion |
| Nov 2, 2026 | 9.56% | KRW 6.99 billion |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Subscription Results of Rights Offering or Equity-linked Bonds (Voluntary)Nov 16, 2026 · Rights OfferingEnglish
- Subscription Results of Rights Offering or Equity-linked Bonds (Voluntary)(Korean)Nov 11, 2026 · Rights Offering
- [Amended] Decision on Acquisition of Shares in Another Company (Subsidiary)(Korean)Nov 6, 2026 · Investment
- [Amended] Decision on Acquisition of Shares in Another Company(Korean)Nov 6, 2026 · Investment
- Issue Price of New Shares in Rights Offering (Notice)Nov 5, 2026 · Rights OfferingEnglish
- [Amended] Decision on Rights OfferingNov 5, 2026 · Rights OfferingEnglish
- Report on Specified Securities Held by Executives and Major ShareholdersNov 4, 2026 · Insider Ownership ReportEnglish
- Report on Specified Securities Held by Executives and Major ShareholdersNov 4, 2026 · Insider Ownership ReportEnglish
Filings with a published English version open in English; the rest link to the Korean original.
Samsung Biologics (207940) stock information
KOSPI
Samsung Biologics (207940) is listed on KOSPI. Its market capitalization is about KRW 65 trillion. On trailing-twelve-month earnings the P/E ratio is 32.75, and the P/B ratio is 7.77. Return on equity is 23.7%. These figures are computed in-house from official filings and are reference information only.
Samsung Biologics — frequently asked questions
- What is the P/E ratio of Samsung Biologics (207940)?
- On a trailing-twelve-month basis, 207940 trades at a P/E ratio of 32.75. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Samsung Biologics?
- 207940 has a market capitalization of about KRW 65 trillion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.